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Background: This multicentre, open-label study evaluated the efficacy and safety of SPI-1620, an analogue of endothelin-1,
administered in combination with docetaxel as second-line treatment for patients with advanced biliary tract cancer (ABTC).
Methods: Eligible patients received continuous cycles of combination therapy with SPI-1620 (11 mg m  2) and docetaxel
(75 mg m  2) intravenously every 3 weeks until disease progression (PD) or intolerable toxicity. Tumour response was evaluated
using computed tomography or magnetic resonance imaging every 2 cycles (6 weeks). The primary efficacy end point was
progression-free survival (PFS); secondary end points included overall response rate (ORR), duration of response, and overall
survival (OS) that were estimated using the Kaplan–Meier method.
Results: Of the 30 enrolled patients, 25 patients had qualifying events (PD or death), 1 patient was nonevaluable, and 4 patients
were censored at the time of their last tumour assessment. Our primary end point of PFS X5 months was not reached. Median PFS
was 2.6 months (95% confidence interval (CI): 1.4–2.8), ranging from 0.7 to 8.4 months. The ORR was 10.3% (95% CI: 0.02–0.27).
Eleven additional patients achieved stable disease. The OS was 4.87 months. The most common grade 3–4 toxicities were febrile
neutropenia and neutropenia.
Conclusions: The addition of docetaxel to SPI-1620 in second-line ABTC did not meet the pre-specified primary end point of PFS
X5 months in unselected patient population.

Biliary tract cancers are a heterogeneous group of invasive
carcinomas that include intrahepatic and extrahepatic biliary tract
cancers and carcinomas arising from the gallbladder and ampulla

of Vater. In the United States, the incidence of extrahepatic biliary
tract cancers is B11 420 per year, and two-thirds of these are
gallbladder cancers. It is difficult to determine the incidence of
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intrahepatic cholangiocarcinoma, but an estimated 39 230 primary
liver and intrahepatic cholangiocarcinomas are diagnosed annually
(Siegel et al, 2016). At presentation, a majority of these cancers are
at an advanced stage – either unresectable or metastatic – and carry
a median survival time of p1 year.
Chemotherapy remains the mainstay of treatment for a majority
of patients with biliary cancers. For first-line treatment, a
gemcitabine/cisplatin regimen is the preferred regimen based on
data from the ABC-02 trial, the largest, randomised phase 3 trial
for the treatment of advanced biliary cancer (Valle et al, 2010).
However, no standard second-line treatment has been established.
A number of studies have demonstrated modest single-agent
activity of several chemotherapeutic agents, such as gemcitabine,
fluorouracil, S-1, oxaliplatin, docetaxel and others, in the treatment
of biliary cancer (Oh et al, 2011; Suzuki et al, 2013; He et al, 2014).
Of these, single-agent docetaxel showed some activity as single
agent in one trial with one complete response and three partial
responses in 21 patients (Papakostas et al, 2001). However, another
study reported no objective responses in 17 patients (Pazdur et al,
1999).
Additional supporting data are derived from retrospective
analyses demonstrating disease control in 45% of patients
(Walter et al, 2013), particularly in those patients with good
performance status who responded to initial chemotherapy (Lee
et al, 2012). There is a clear need for further study of more efficient
and tolerable regimens in biliary cancers.
A potential mechanism for the modest efficacy of chemotherapy
regimens in biliary tract cancers is the failure to achieve adequate
cytotoxic concentrations at the tumour bed because of poor
penetration and nonuniform drug distribution within the tumour
(Jain, 1991). A new approach has been proposed that involves
targeting receptors on the tumour vasculature. One such group of
receptors is the endothelin (ET) receptor family that are widely
distributed throughout the body and are involved in a variety of
physiological functions (Brooks et al, 1995; Nelson et al, 2003). The
ET receptors exert their effects by binding to two distinct types of cell
surface receptors, ETA and ETB. It has been shown that both ETA
and ETB receptors are overexpressed in breast cancer (Rajeshkumar
et al, 2005) and prostate (Rajeshkumar et al, 2007) tumour models in
rats and melanoma and ovarian tumour models in mice (data on
file). Consequently, it may be possible to use selective ETB receptor
agonists to transiently increase tumour blood perfusion and enhance
delivery of antineoplastic agents to solid tumours.
SPI-1620, previously known as IRL 620 or N-Suc-[Glu9,
Ala11,15]ET-1(8–21), is an investigational, highly selective peptide
agonist of ETB receptors expressed on endothelial cell lining the
interior surface of blood vessels (Yanagisawa et al, 1988).
Preclinical studies of SPI-1620 in several different tumour models
suggest that it stimulates ETB receptors on tumour vascular,
selectively and transiently increasing tumour blood flow and
improving delivery of anticancer agents to the tumour
(Rajeshkumar et al, 2005, 2007). The SPI-1620 has been shown
to enhance the anticancer activity of paclitaxel and cisplatin in
animal studies (Rai et al, 2005; Rajeshkumar et al, 2005).
A phase 1, open-label study of SPI-1620 in combination with
docetaxel was conducted in 36 patients with recurrent or
progressive carcinoma, including 2 patients with refractory
cholangiocarcinoma (Tolcher et al, 2011). In cycle 1, patients
received escalating doses of SPI-1620 ranging from 0.5 to
15.1 mg m  2 (no intrapatient escalation) on days 1 and 8 alone,
and on day 15, patients were given SPI-1620 followed by docetaxel
on day 1 every 21 days. Based on the results of this study, the SPI1620 maximum tolerated dose of 11 mg m  2 was selected for
further study. One of the two patients with biliary cancer who had
lung and liver metastases and had previously been treated with
gemcitabine, cisplatin, and 5-fluorouracil exhibited a complete
disappearance of lung metastases and a partial response of the liver
2
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metastases. Based on these early results and the preclinical
rationale, a phase 2 study of SPI-1620 and docetaxel in the
second-line treatment of patients with refractory bile duct tumours
was conducted.
PATIENTS AND METHODS

This phase 2, multicentre, nonrandomised, open-label clinical
study was designed to evaluate the efficacy and safety of SPI-1620
administered in combination with docetaxel in patients with
advanced biliary tract cancers who had failed one prior
chemotherapy regimen. Before study initiation, the clinical study
protocol and written informed consent form (ICF) were reviewed
and approved by an independent ethics committee or internal
review board, as required by law. The investigators agreed to
comply with the World Medical Association Declaration of
Helsinki concerning written informed consent and the protection
and rights of human subjects.
Eligibility criteria. Eligible patients had histologically confirmed
biliary tract or gallbladder cancer that had relapsed or was
refractory after one prior gemcitabine-based chemotherapy regimen for advanced disease. Patients were allowed to have received
adjuvant treatment if their relapse had occurred within 1 year post
gemcitabine-based chemotherapy regimen. Measurable disease was
required. Other eligibility criteria included a Zubrod performance
status of 0–1; adequate bone marrow function indicated by a
leukocyte count X3000 per ml, absolute neutrophil count X1000
per ml, and platelet count X75,000 per ml; adequate hepatic
function with a total bilirubin up to 2.5  the institutional upper
limit of normal; aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) levels p2.5 the upper limit of normal.
Patients with congestive heart failure or myocardial infarction and
significant circulatory disorders in the past 6 months, stroke,
significant ventricular arrhythmia, or inadequately controlled
hypertension were excluded.
The evaluable population was defined as all patients who
received at least one dose of both SPI-1620 and docetaxel and had
at least one post-baseline tumour response assessment using
Response Evaluation Criteria in Solid Tumours (RECIST) versions
1.1. The safety population was defined as all patients who received
at least one dose of SPI-1620 or docetaxel.
Treatment. Eligible patients received 11 mg m  2 of SPI-1620
intravenously (IV) over 1 min on day 1 of each cycle, with dose
reductions permitted to 9 and 7 mg m  2 for toxicity. At 10 min (±2)
after SPI-1620 administration, patients received docetaxel
75 mg m  2 IV, with dose modification in accordance with the
Taxotere (Sanofi-aventis Bridgewater, NJ, USA) prescribing information. This regimen was repeated in 3-week (21-day) cycles until
progression or intolerable toxicity. Specific dose modification and
treatment interruption criteria for docetaxel and SPI-1620 were
applied. If docetaxel was held for specific toxicity, then SPI-1620 was
held; however, if SPI-1620 was held because of toxicity, then
docetaxel was given by itself. Docetaxel dose modification was
permitted, as per Taxotere prescribing information. Two dose
reductions were allowed for SPI-1620. The SPI-1620 dose reduction
or discontinuations were necessary in the event of hypersensitivity
reactions, hypotension, or bronchospasm. For mild-to-moderate
infusion reactions, the infusion rate was decreased by 50% for the
remainder of the dose. If severe infusion reactions occur,
discontinuation of therapy was recommended.
Assessment of efficacy and toxicity and statistical considerations. The primary end point of the trial was progression-free
survival (PFS) in patients with advanced gallbladder cancer or
cholangiocarcinoma treated with docetaxel and SPI-1620.
www.bjcancer.com | DOI:10.1038/bjc.2017.160
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Progression-free survival was calculated as the time from the first
dose of study treatment to the first observation of a qualifying PFS
event (progression of disease or death). For patients without an
event, PFS was censored at the time of the last evaluable disease
assessment.
We hypothesised that combination therapy with SPI-1620 and
docetaxel would have been of further interest if the median PFS
had been X5 months (PFS rate of X44% at 6 months) and was
deemed ineffective if the median PFS was p3 months (PFS rate of
p25% at 6 months). With a significance level of 5% and power of
80%, 39 patients were planned to be treated. The study would have
been considered positive if at least 15 patients had been
progression free after 6 months.
Secondary efficacy end points were overall response rate (ORR)
(proportion of patients achieving complete response (CR) or partial
response (PR)); duration of response (time from first response to first
documentation of progression of disease (PD) or death); and overall
survival (OS) (time from the first dose of study treatment to death
because of any cause). Distribution of PFS, duration of response, and
OS were estimated using the Kaplan–Meier method. The safety end
points were worst grade adverse events (AEs); deaths, other serious
adverse events (SAEs), and AEs leading to discontinuation of study
treatment; and worst grade laboratory abnormalities.
Patients were seen and evaluated on a weekly basis during cycle 1,
and every 3 weeks in cycle 2 and beyond. Tumour response was
evaluated using computed tomography (CT) or magnetic resonance
imaging (MRI) in accordance with the RECIST (version 1.1).
Disease assessments were performed at baseline and every two cycles
(6 weeks) during the treatment period and every 6 to 8 weeks after
discontinuation for reasons other than progressive disease (PD);
assessments continued until documented PD or first subsequent
therapy for biliary cancer, whichever occurred first. Survival followup was performed every 3 months following the last tumour
assessment and continued until 2 years from the start of study
treatment or until study closure. For patients without an event, PFS
was censored at the time of the last evaluable disease assessment.
Measurable disease was defined as at least one lesion for which
the longest diameter could be accurately measured as X1 cm using
spiral CT or MRI. Measurable lymph nodes had to have a shortaxis measurement of X1.5 cm. All other lesions, including ascites
and pleural effusions, were considered non-measureable. Blood
samples for tumour markers carcinoembryonic antigen (CEA) and
cancer antigen (CA) 19-9 were collected at baseline and, if
abnormal, every two cycles (6 to 7 weeks) thereafter.
Safety measurements included AEs, physical examinations, vital
signs, clinical laboratory assessments, and electrocardiograms.
Adverse events considered related to study procedures were collected
from the time informed consent was obtained until the administration of the first dose of study treatment, after which all AEs were
recorded through 30 days after the last dose of study treatment.
From 31 days after the last dose of study treatment, only treatmentrelated AEs were recorded. Adverse events were graded according to
the National Cancer Institute (NCI) Common Terminology Criteria
for Adverse Events (CTCAE), version 4.03, grouped by Medical
Dictionary for Regulatory Activities (MedDRA) preferred term, and
summarised by worst grade severity. Treatment-emergent AEs
(TEAEs) were defined as AEs that occurred or worsened at the time
of or after the first dose of study treatment, or any treatment-related
AEs, regardless of the time of onset. Clinical laboratory results were
classified according to the NCI CTCAE version 4.03.

RESULTS

Patient disposition. A total of 30 patients were enrolled in the
study between August 2013 and July 2015. Reasons for study
www.bjcancer.com | DOI:10.1038/bjc.2017.160
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Table 1. Demographics and baseline characteristics
Baseline characteristic

SPI-1620 (N ¼ 30)

Age (years)
Mean (s.d.)

30
63.0 (9.94)

Median
Min, max

64
42, 80

Gender
Female, n (%)
Male, n (%)

14 (46.7%)
16 (53.3%)

Ethnicity
Missing, n (%)
Hispanic or Latino, n (%)
Not Hispanic or Latino, n (%)

3 (10.0%)
2 (6.7%)
25 (83.3%)

Race
Asian
Declined to answer
Declined to state
White

1
1
2
26

ECOG Performance Status
0
1
2

9 (30%)
20 (67%)
1 (3%)

Primary site
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Gallbladder cancer

22 (73%)
7 (23%)
1 (3%)

Disease status
Locally advanced
Metastatic

2 (7%)
28 (93%)

Prior cancer surgery
Yes
No

16 (53%)
14 (47%)

Prior chemotherapy
Gemcitabine þ cisplatin
Gemcitabine þ oxaliplatin
Gemcitabine

21 (70%)
6 (20%)
3 (10%)

(3.3%)
(3.3%)
(6.7%)
(86.7%)

Abbreviation: ECOG ¼ Eastern Cooperative Oncology Group.

treatment discontinuation were: disease progression (n ¼ 13,
43.3%), withdrawal of consent (n ¼ 5, 16.7%), death (n ¼ 4,
13.3%), adverse events (n ¼ 3, 10.0%), other (n ¼ 3, 10.0%),
physician decision (n ¼ 1, 3.3%), and sponsor decision (n ¼ 1,
3.3%).
Treatment exposure. All but 1 patient received at least one dose
of SPI-1620 and docetaxel; therefore, the safety population
consisted of 29 (96.7%) patients. The median total dose of SPI1620 and docetaxel administered were 43 mg (range: 20–275 mg)
and 292 mg (range: 111–1361 mg), respectively. The median
number of cycles administered was two (range: 1–12).
Demographics and baseline characteristics. As shown in Table 1,
slightly more male than female patients were enrolled (53.3% vs
46.7%). The majority of patients were not Hispanic or Latino
(83.3%) and White (86.7%), and the median age was 64 years
(range: 42–80 years). The majority of patients were ECOG
Performance Status 1 (67%) or 2 (30%). Most patients (73%)
had intrahepatic cholangiocarcinoma or extrahepatic cholangiocarcinoma (23%). The vast majority of patients (93%) had
metastatic disease. Slightly more patients had received prior cancer
surgery (53% vs 47%, no surgery). Finally, prior chemotherapy
consisted of gemcitabine and cisplatin for 70%, gemcitabine plus
oxaliplatin (20%), and gemcitabine monotherapy (10%).
Safety and tolerability. As shown in Table 2, all treated patients
experienced at least one treatment-emergent AE, and most patients
(n ¼ 28, 96.6%) experienced at least one treatment-related AE.
3
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Table 2. Overall summary of adverse events (safety
population)
SPI-1620 (N ¼ 29)
Adverse events (AEs)

Subjects resulting in death due to AE

29 (100.0%)
4 (13.8%)

Subjects with AE by severity grade
1: Mild
2: Moderate
3: Severe
4: Life threatening
5: Fatal
6: Missing

28
27
24
16
4
1

Subjects with AE by relationship to study drug
Related
Not related
Missing

28 (96.6%)
28 (96.6%)
1 (3.4%)

Outcome
Recovered/resolved
Recovered/resolved with sequelae
Not recovered/resolved
Fatal
Missing

29
12
16
4
1

Subjects with at least one serious AE

19 (65.5%)

Subjects resulting in death due to serious AE

(96.6%)
(93.1%)
(82.8%)
(55.2%)
(13.8%)
(3.4%)

SPI-1620 (N ¼ 29) N (%)

Subjects with at least one treatment-related SAE

8
5
2
1

(27.6%)
(17.2%)
(6.9%)
(3.4%)

Gastrointestinal disorders
Ascites
Small intestinal obstruction

2 (6.9%)
1 (3.4%)
1 (3.4%)

General disorders and administration-site
conditions
Mucosal inflammation

1 (3.4%)

Investigations
Neutrophil count decreased
White blood cell count decreased

1 (3.4%)
1 (3.4%)
1 (3.4%)

1 (3.4%)

Abbreviation: SAE ¼ serious adverse event.

4 (13.8%)

1.0

SPI-1620 (N = 29)
Median:
4.87
95% CI: (3.12–NE)

0.8
0.6
0.4
0.2

Total N ¼ 29 (%)

Number of patients with any treatment-related TEAE

28 (96.6%)

Fatigue

18 (62.1%)

0.0
0

2

4

Anaemia

8 (27.6%)

Nausea

8 (27.6%)

SPI-1620 29

Neutropenia

8 (27.6%)

Solid circles represent censored

White blood cell count decreased

8 (27.6%)

Decreased appetite

7 (24.1%)

Diarrhoea

6 (20.7%)

Febrile neutropenia

5 (17.2%)

Hot flush

5 (17.2%)

Neutrophil count decreased

5 (17.2%)

Abbreviation: TEAE ¼ treatment-emergent adverse event.

Overall, 19 (65.5%) patients experienced at least one SAE,
including 11 patients (37.9%) with SAEs assessed as related to
study treatment (Table 4). Severe (grade 3) AEs were reported at
least once in 24 patients (82.8%), and life-threatening (grade 4)
AEs were reported at least once in 16 patients (55.2%). Eight
patients (27.6%) experienced AEs leading to discontinuation of
study treatment.
As shown in Table 3, the most commonly occurring treatmentrelated AEs were fatigue (n ¼ 18, 62.1%); anaemia, nausea,
neutropenia, and leukopenia (n ¼ 8, 27.6% each); decreased
appetite (n ¼ 7; 24.1%); diarrhoea (n ¼ 6; 20.7%), and febrile
neutropenia, hot flush, and neutropenia (n ¼ 5, 17.2% each).
The most frequently reported grade 3 AEs (42 patients) were
anaemia and febrile neutropenia (each n ¼ 5, 17.2%); abdominal
pain, ascites, fatigue, and neutropenia (n ¼ 4, 13.8%); and anorexia
(n ¼ 3, 10.3%). Grade 4 AEs included neutropenia (n ¼ 8, 27.6%);
white blood count (WBC) decreased (n ¼ 6, 20.7%); neutrophil
count decreased (n ¼ 4, 13.8%); and anaemia, dyspnoea, lymphocyte count decreased, urinary tract infection, and vomiting (each
n ¼ 1, 3.4%).
4

11 (37.9%)

Blood and lymphatic system disorders
Febrile neutropenia
Neutropenia
Anaemia

(100.0%)
(41.4%)
(55.2%)
(13.8%)
(3.4%)

Table 3. Most common (X5 subjects) treatment-related
adverse events (all grades)
Preferred term

Preferred term

Survival rate

Subjects with at least one AE

508

Table 4. Summary of serious (Xgrade 3) treatment-related
adverse events (safety population)

6

8
10
Months

12

4

3

1

14

16

18

Number of patients at risk:
21

14

2

0

Figure 1. Overall survival. NE ¼ not estimated.

For 19 patients (65.5%), at least one event was an SAE. The
most frequently reported SAEs (41 patient) were febrile
neutropenia (n ¼ 6, 20.7%), disease progression (n ¼ 4, 13.8%)
and abdominal pain, ascites, dyspnoea, and neutropenia (each
n ¼ 2, 6.9%). Treatment-related SAEs were largely haematologic, as
presented in Table 4.
Sixteen patients (55.2%) died on study, all because of PD.
Efficacy. In the analysis of PFS, 25 patients had qualifying events
(PD or death), and 4 patients were censored at the time of their last
tumour assessment. The median PFS was 2.6 months (95%
confidence interval (CI): 1.4–2.8), with individual patient PFS
ranging from 0.7 to 8.4 months. The ORR (patients with either a
CR or PR) was 10.3% (95% CI: 0.02–0.27), and 11 patients
achieved stable disease. There were no complete radiographic
responses. No disease-specific subset analyses were performed
because of the small number of patients. Overall survival was 4.87
months (Figures 1 and 2).
DISCUSSION

In this multicentre, open-label phase 2 trial, we explored the
efficacy and safety of SPI-1620, an analogue of endothelin-1,
administered in combination with docetaxel in patients with
ABTC. Ampullary carcinoma was excluded from this study, as it
portends a more favourable prognosis of than other biliary tract
www.bjcancer.com | DOI:10.1038/bjc.2017.160
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Progression-free rate

1.0

SPI-1620 (N = 29)
2.56
Median:
95% CI: (1.41–2.79)

0.8
0.6
0.4
0.2
0.0
0

2

4

6
Months

5

1

8

10

Number of patients at risk:
SPI-1620

25

12

0

Solid circles represent censored

Figure 2. Progression-free survival.

cancers (Albores-Saavedra et al, 2009). The sponsor decided to
close the study after 30 patients had been treated, owing to the
failure to meet predetermined median PFS end point. Specifically,
we had specified that SPI-1620 would be deemed to have good
activity if 15 or more patients out of 39 were progression free after
6 months of treatment. However, after 30 patients, it was clear that
our goal of 15 patients would not be reached, especially given that
only 2 patients exhibited a PFS of 46 months.
This study was based on the hypothesis that the use of SPI-1620
in combination with docetaxel would transiently and selectively
increase perfusion of the chemotherapeutic agent into tumour
tissue without increasing chemotherapy exposure. Despite the
robust preclinical data suggesting that using SPI-1620 can alter
vascular permeability and enhance drug delivery in biliary
tumours, this study failed to demonstrate significant activity in
biliary cancer. Furthermore, toxicity was also a concern, with 38%
of patients experiencing grade 3 toxicity. The median PFS and OS
were 2.56 and 4.86 months, respectively. In retrospect, it is clear
that our goal of achieving a primary end point of median PFS time
of X5 months was too ambitious. Current phase 3 data of secondline chemotherapy in advanced biliary cancer are lacking; therefore, the target median PFS or OS in the second-line setting is
unclear. Available data are derived primarily from small prospective studies or retrospective data. The largest retrospective study
conducted to date was from the Princess Margaret Hospital that
included 378 patients with advanced biliary tumours. The authors
evaluated the benefit of various second-line chemotherapy regimens and demonstrated a PFS of 2.8 months and an OS of 7.5
months (Walter et al, 2013). Another retrospective study involving
56 patients and evaluating various second-line chemotherapy
regimens like gemcitabine and 5-fluorouracil reported a similar
PFS of 2.8 months but a better median OS of 13.8 months (Rogers
et al, 2014). Other small, prospective studies included small
numbers of patients with PFS ranging from 1.6 to 5.4 months (Oh
et al, 2011; Sasaki et al, 2012). However, no definitive conclusion
can be drawn, as none of these studies were randomised. Currently,
there is a prospective trial being conducted in the United Kingdom
where patients are being randomised to receive either 5fluorouracil/oxaliplatin or best supportive care alone in the
second-line setting (Clinicaltrials.gov).
Bevacizumab, an antivascular endothelial growth factor monoclonal antibody, has been studied in phase 2 studies in advanced
biliary cancer. Although generally the outcomes have been
encouraging, these studies were primarily conducted in the firstline setting. For example, the combination of bevacizumab with
gemcitabine and oxaliplatin achieved an OS of 10 months and a
response rate (RR) of 44% (Zhu et al, 2010). Furthermore, one
retrospective study evaluated the use of FOLFIRI plus bevacizumab
in the refractory setting and demonstrated promising results, with
www.bjcancer.com | DOI:10.1038/bjc.2017.160
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a PFS of 8 months and an OS of 20 months (Guion-Dussere et al,
2015). However, once again, the results of these studies are limited
because of their retrospective nature and small number of enrolled
patients. Cabozantinib, a multikinase inhibitor with potent activity
against vascular endothelial growth factor receptor 2 (VEGFR2)
and MET, was performed for patients with advanced refractory
cholangiocarcinoma in a small phase 2 study (Goyal et al, 2017).
Similar to our study, the drug had limited activity in unselected
patients with cholangiocarcinoma and significant toxicity.
Our study has several limitations, including the small patient
population and its nonrandomised study design. Furthermore, the
incidence of grade 3/4 toxicities was high and they were primarily
haematologic in nature. This may have been attributable to the
selection of docetaxel as the backbone chemotherapy to use in
combination with SPI-1620. In the previous study of docetaxel in
cholangiocarcinoma, 76% of the patients experienced grade 4
neutropenia and 65% experienced febrile neutropenia. Once again,
in retrospect, docetaxel may have not been the best choice;
however, as no standard second-line chemotherapy has been
identified, it is unclear which chemotherapy may have yielded
better results. Evidence does suggest that perhaps the selection of
capecitabine, with its more favourable haematologic safety profile,
may have improved efficacy and safety.
CONCLUSION

In conclusion, the combination of SPI-1620 and docetaxel did not
meet its primary end point in an unselected population of patients
with advanced biliary cancer. Future studies in the second-line
setting should select patients based on tumour location, tumour
biology, and biomarkers. Furthermore, randomised studies are
desperately needed in the second-line setting to establish standards
of care.
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